Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Table 6 Base case results, Sweden

	Cost components (EUR)
	Treatment costs	GP/A&E visits	Hospital	Triptan treatment	Total direct costs
*Botox*	8535	12,949	1338	472	23,293
*Placebo*	2749	14,087	1488	522	18,846
	Total and incremental results
	Total costs (EUR)	Discounted total costs (EUR)	Incremental cost (EUR)	Total QALYs	Discounted QALYs	Incremental QALYs	ICER
*Botox*	23,293	20,700	4126	6.505	5.711	0.223	18,506
*Placebo*	18,846	16,574	4126	6.257	5.488	0.223	18,506

Key: A&E Accident and emergency; GP General practitioner; ICER Incremental cost-effectiveness ratio; QALY Quality adjusted life years. Note: Treatment costs include the administration cost for Botox and the neurologist visits for both Botox and placebo

ISSN: 1129-2377